Strongbridge Biopharma — Q2 2018 Earnings Presentation
33 slides from Strongbridge Biopharma's earnings presentation, Aug 8, 2018
Slide 1: Forward-looking statements
Forward-looking statements This document contains forward-looking statements relating to the Company’s strategy, objectives, business development plans and financial position. All statements other than statements of historical facts included in this document, including, without limitation, statement
Slide 2: Building a portfolio of therapeutically-aligned vertical franchises in rare diseases
Strongbridge Biopharma plc: Building a portfolio of therapeutically-aligned vertical franchises in rare diseases Rare Endocrine Rare Neuromuscular Rare Disease Franchise #3 MACRILEN (macimorelin) The 1st and only FDA-approved oral drug for diagnosing adult growth hormone deficiency (Orphan Drug Excl
Slide 3: Recent and anticipated milestones
Recent and anticipated milestones 2H - 20181H -2019 Macrilen Commercial launch (July 2018) Quarterly sales updates RecorlevSONICS Top-line data (August 2018) SONICS Additional data (Q4 2018) SONICS Top-line one-year data (Q1 2019) LOGICS Top-line data (Q1 2019) Keveyis Quarterly sales updates Quarte
Slide 4: Recorlev (levoketoconazole)
Recorlev (levoketoconazole)
Slide 5: Cushing's syndrome complications and comorbidities
Cushing’s syndrome complications and comorbidities Psychosis, impaired memory, sleep disturbance, depression, anxiety Heart attacks, stroke, high blood pressure, high cholesterol, vein clots Overweight/obesity, facial, neck and abdominal fat accumulation, diabetes Muscle and skin atrophy Osteoporosi
Slide 6: Phase 3 Cushing's syndrome clinical program
Phase 3 Cushing’s syndrome clinical program 94 Patients EnrolledBoth are pivotal trials to support FDA regulatory DOSE TITRATION: 2 to 21 weeks Titrate in 150 mg increments up to max 600 mg 2x daily until UFC normalization is achieved MAINTENANCE: 6 months Maintain UFC normalization with fixed thera
Slide 7: SONICS Study Design: Single Arm, Open-Label Phase 3
SONICS Study Design: Single Arm, Open-Label Phase 3 2 – 21 weeks 6 months 6 months Dose Titration Maintenance Extended Evaluation Increase dose in 150mg increments up to max of 600mg 2x daily until UFC normalization Maintain UFC normalization for 6 months with no dose increase Primary endpoint 94 pa
Slide 8: SONICS Patient Demographics
SONICS Patient Demographics
Slide 9: Full and Partial UFC Responder Analysis At End Of Maintenance Phase
Full and Partial UFC Responder Analysis At End Of Maintenance Phase Analysis based on repeated measures model. Least squares mean estimate and associated 95% confidence interval CI: 95% Confidence interval around the least squares means estimate from repeated measures model *1-sided vs. null hypothe
Slide 10: SONICS Key Secondary Endpoints at Month 6
SONICS Key Secondary Endpoints at Month 6 *Hochberg adjustment applied to p-values to control type 1 error (except Body Mass Index); reductions from baseline based on least squares mean changes from repeated measures model. No significant changes observed in blood pressure or c-reactive protein; sma
Slide 11: SONICS Liver-Related Lab Values
SONICS Liver-Related Lab Values *No severe drug-induced liver injury; no Hy’s law; no transaminases >20x ULN; no obvious dose relationship (exposure relationships analyses pending)
Slide 12: Most common reported AEs
Most common reported AEs (>=15%, both phases combined) *Includes all alanine aminotransferase (ALT) increases reported as an adverse event regardless of level or relationship to drug. A subset of these ALT increased events was also reported as adverse events of special interest.
Slide 13: Recorlev Next Steps
Recorlev Next Steps Strongbridge intends to discuss accelerated approval and the regulatory pathway with the FDA Report one year safety and efficacy data from SONICS (Q1 2019) Complete enrollment and report results (Q1 2019) from Phase 3 randomized withdrawal LOGICS study
Slide 14: Recorlev U.S. Commercial Opportunity
Recorlev U.S. Commercial Opportunity Patient Population Estimated US diagnosed prevalence ~25,000 •If approved, position Recorlev as first-line, first-choice therapy •Based on SONICS data, Recorlev launch strategy could also include targeting off-label Active disease: addressable ~7,000 Active disea
Slide 15: Recorlev U.S. Commercial Opportunity
Recorlev U.S. Commercial Opportunity ] Patient Population If approved, position Recorlev as first-line, first-choice therapy Based on SONICS data, Recorlev launch strategy could also include targeting off-label ketoconazole switches (~2,000-3,000 patients) Targeted pricing corridor of ~$200K-$400K p
Slide 16: Macrilen
Macrilen Macrilen is an oral ghrelin receptor agonist (secretagogue) administered to stimulate growth hormone production FDA approval in December 2017 for use in the diagnosis of patients with AGHD Strongbridge acquired U.S. and Canadian rights in January 2018 and launched Macrilen in the United Sta
Slide 17: Adult growth hormone deficiency (AGHD)
Adult growth hormone deficiency (AGHD) Symptoms Causes • Body composition altered: • Increased fat mass • Decreased lean body mass • Reduced skeletal muscle strength • Cardiovascular (CV) issues: • Increased risk of CV death • Abnormal lipids, other risk markers • Bone mineral density: • Increased f
Slide 18: Many patients are not screened for AGHD
Many patients are not screened for AGHD due to the complexity, tolerability and safety issues of the current tests NOT FDA APPROVED 1. Yuen KCJ. South Dartmouth, MA; Endotext [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK395585/. Accessed February 19, 2018. 2. Agrawal V, Garcia JM. The macimorel
Slide 19: Macrilen: 1st and only FDA-approved oral drug for diagnosing AGHD
Macrilen: The 1st and only FDA-approved oral drug for diagnosing adult growth hormone deficiency (AGHD)
Slide 20: Macrilen accurately diagnoses AGHD: comparison to ITT
Macrilen accurately diagnoses AGHD: comparison to ITT Insulin Tolerance Test (ITT) (GH cutoff 5.1 ng/mL) Positive Negative Total Tests Macrilen (GH cutoff 2.8 ng/mL) Positive 55 4 59 Negative 19 62 81 Total 74 66 140 AGRE EMENT 74%* 94%* 84% •Positive agreement higher (89%) for high-risk AGHD catego
Slide 21: Macrilen Safety Summary
Macrilen Safety Summary •Macrilen well tolerated as compared to ITT (see table) •Most common adverse reactions with Macrilen: •Dysgeusia (4.5%); dizziness, fatigue, and headache (3.9% each); nausea (3.2%) •Most adverse reactions were mild; none severe or led to failure to complete test •QTcF upper 9
Slide 22: Macrilen Market Opportunity
Macrilen Market Opportunity 40-60k Annual Tests* 33% increase in AGHD testing** TBI’s 2.8M per year*** (on-label: no further clinical studies needed) Pre-Macrilen Potential Post-Macrilen Growth Opportunity • Expected increase in testing for AGHD because of Macrilen WAC price per unit of $4,500 • All
Slide 23: Flexible and Scalable Distribution & Services Model
Flexible and Scalable Distribution & Services Model Third-Party Logistics Specialty Distributors Specialty Wholesale Distribution HOPD*, Physician Clinic, VA Specialty Pharmacy Network Macrilen Service Center Reimbursement and Order Triage Specialty Pharmacy Distribution Inbound Service Requests Phy
Slide 24: Veldoreotide Extended Release
Veldoreotide Extended Release
Slide 25: Veldoreotide extended release: a novel, multi-receptor somatostatin analog
Veldoreotide extended release: a novel, multi-receptor somatostatin analog BACKGROUND Acquired immediate-release formulation of veldoreotide in 2015 and focused initial R&D on long-acting reformulation 10/2016: Successfully formulated for convenient, at-home, subcutaneous administration using PLGA m
Slide 26: Keveyis (dichlorphenamide)
Keveyis (dichlorphenamide) The first and only FDA-approved therapy for primary periodic paralysis* * FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis
Slide 27: Primary periodic paralysis: a spectrum of rare, chronic, genetic, neuromuscular disorders
Primary periodic paralysis: a spectrum of rare, chronic, genetic, neuromuscular disorders PPPSymptoms/triggersImpact of attacks Frequency Causes recurrent, progressive, and debilitating episodes of muscle weakness and temporary paralysis2-4 ~4-5k patients in the U.S. 5 Symptoms: clumsiness, extreme
Slide 28: Keveyis revenue
Keveyis revenue Q2 2018 actual FY 2018 guidance $4.3m $18-20m
Slide 29: Keveyis revenue
| Keveyis revenue Q2 2018 FY 2018 actual guidance $4.3m $18-20m MGroncoppce 29 BIOPHARMA
Slide 30: Intellectual property and orphan exclusivity
Intellectual property and orphan exclusivity
Slide 31: Strong Balance Sheet to Support Growth Objectives
Strong Balance Sheet to Support Growth Objectives $86m Cash $87m Debt $205m Market Capitalization 46.7m ordinary shares 64.3m fully diluted shares Sufficiently capitalized with cash and potential additional borrowings to fund operations through Recorlev approval and launch to cash flow positive Cash
Slide 32: Strong Balance Sheet to Support Growth Objectives
Strong Balance Sheet to Support Growth Objectives Sufficiently capitalized with cash and potential additional borrowings to fund operations S205 46.7m ordinary shares through Recorlev Capitalization 64.3m fully diluted shares @mproval and launch to cash flow positive Sean ener eaten er erent ee are
Slide 33: Strongbridge Biopharma plc
Strongbridge Biopharma plc
Strongbridge Biopharma — Q2 2018 Earnings Presentation on 6ix